Department of Experimental Clinical Oncology

Error in site JavaScript
Untitled Document

PUBLICATIONS 2003

 

671.      Agerbæk, M., Alsner, J., Marcussen, N., Lundbeck, F. & von der Maase, H.: Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer. Brit. J. Cancer 89: 298-304, 2003.

672.      Alsner, J.: Isolation and sequencing of heteroduplex fragments from DHPLC analysis of somatic, low-frequency mutations. In Genetic Variance Detection~Nuts & Bolts of DHPLC in Genomics, K.H. Hecker, ed., DNA Press, LLC, pp. 163-173, 2003.

673.      Andreassen, C.N., Grau, C. & Lindegaard, J.C.: Chemical radioprotection; a critical review of amifostine as cytoprotector in radiotherapy. Sem. Rad. Oncol. 13: 62-72, 2003.

674.      Andreassen, C.N., Alsner, J., Overgaard, M. & Overgaard, J.: Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother. Oncol. 69: 127-135, 2003.

675.      Bach, LA, Sumpter, DJT, Alsner, J, & Loeschcke, V. Spatial Evolutionary Games of Interaction among Generic Cancer Cells. J. Ther. Med. 5: 47-58, 2003.

676.      Bentzen, L., Keiding, S., Nordsmark, M., Falborg, L., Hansen, S.B., Keller, J., Nielsen, O.S. & Overgaard, J.: Tumour oxygenation assessed by  [18F]fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother. Oncol. 67: 339-344, 2003.

677.      Celis, J.E., Gromov, P., Gromova, I., Moreira, J.M., Cabezon, T., Ambartsumian, N., Grigorian, M., Lukanidin, E., Straten P.T., Guldberg, P., Bartkova, J., Bartek, J., Lukas, J., Lukas, C., Lykkesfeldt, A., Jaattela, M., Roepstorff, P., Bolund, L., Orntoft, T., Brunner, N., Overgaard, J., Sandelin, K., Blichert-Toft, M., Mouridsen, H. & Rank, F.E..: Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol. Cell Proteomics. 2: 369-77, 2003.

678.      Theilgaard, S.A., Buchwald, C., Ingeholm, P., Kornum Larsen, S., Eriksen, J.G. & Sand Hansen, H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol. 123:433-9, 2003.

679.      Grau, C., Agarwal, J.P., Jabeen, K., Khan, A.R., Abeyakoon, S., Hadjieva, T., Wahid, I., Turkan, S., Tatsuzaki, H., Dinshaw, K.A. & Overgaard, J.: Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer. Results of the IAEA multicentre randomised trial. Radiother. Oncol. 67: 17-26, 2003.

680.      Grau, C., Johansen, L.V., Hansen, H.S., Andersen, E., Godballe, C., Andersen, L.J., Hald, J., Møller, H., Overgaard, M., Bastholt, L., Greisen, O., Harbo, G., Hansen, O. & Overgaard, J.: Salvage laryngectomy and pharyngocutaneous fistulae after primary radiotherapy for head and neck cancer. A national survey from DAHANCA. Head & Neck 25: 711-716, 2003.

681.      Graversen, L.: Role of polymerase beta and BER repair in determining ionizing radiation sensitivity. “Forskningsårsopgave”, Faculty of Health Sciences, University of Aarhus, 2003.

682.      Gregoire, V., Levendag, P., Ang, K.K., Bernier, J., Braaksma, M., Budach, V., Chao, C., Coche, E., Cooper, J.S., Cosnard, G., Eisbruch, A., Emami, B., Grau, C., Hamoir, M., Lee, N., Maingon, P., Muller, K. & Reychler, H.:  CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, RTOG consensus guidelines. Radiother. Oncol. 69: 227-236, 2003.

683.      Hald, J., Overgaard, J. & Grau, C.: Evaluation of objective measures of smoking status. A prospective clinical study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncologica 42: 154-159, 2003.

684.      Hansen, S., Overgaard, J., Rose, C., Knoop, A., Lænkholm, A.-V., Andersen, J., Sørensen, F.B. & Andreasen, P.A.: Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1in breast cancer patients. Brit. J. Cancer 88: 102-108, 2003.

685.      Horsman, M.R. & Murata, R.: Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int. J. Radiat. Oncol. Biol. Phys. 57: 1047-1055, 2003.

686.      Jensen, A.R., Ewertz, M., Cold, S., Storm, H.H. & Overgaard, J.: Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark. Eur. J. Cancer 39: 1783-1793, 2003.

687.      Jensen, A.R., Garne, J.P.., Storm, H.H., Ewertz, M., Cold, S., Alvegaard, T. & Overgaard, J.: Stage and survival in breast  cancer patients in screened and non-screened Danish and Swedish populations. Acta Oncologica 42: 701-709, 2003.

688.      Jensen, A.R., Storm, H.H., Møller, S. & Overgaard, J.: Validity and representativity in the Danish Breast Cancer Cooperative Group. A study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncologica 42: 179-185, 2003.

689.      Johansen, L.V., Grau, C. & Overgaard, J.: Laryngeal carcinoma – multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. Acta Oncologica 42: 771-778, 2003.

690.      Knap, M., Lundbeck, F. & Overgaard, J.: The role of pelvic lymph node dissection as a predictive and prognostic factor in bladder cancer. Eur. J. Cancer. 39: 604-13, 2003.

691.      Knap, M., Lundbeck, F. & Overgaard, J.: Prognostic factors, pattern of recurrence and survival in a Danish bladder cancer cohort treated with radical cystectomy. Acta Oncologica 42: 160-168, 2003.

692.      Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for  clinical trials. Br J Radiol. 76: Spec No 1:S87-91, 2003.

693.      Lohr, F., Herskind, C., Lohr, J., Wenz. F. & Li, C-Y.: Enhancement of the radiation response with interleukins/interferons. In:  L.Milas, K.K.Ang and C.Nieder (eds). Modification of Radiation Response. Cytokines, Growth factors, and other Biological Targets. Springer-Verlag, Berlin Heidelberg New York, pp. 205-226, 2003.

694.      Nielsen, H.M., Christensen, J.J., Aagaard, T., Thingholm, J., Overgaard, M. & Grau, C.: A simple method to test if the internal mammary lymph nodes are covered by the wide tangent technique in radiotherapy for high-risk breast cancer.  Clinical Oncology 15: 17-24, 2003.

695.      Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S.-C., Ladekarl, M., Havsteen, H., Lindegaard, J.C., Davidson, S.E., Varia, M., West, C., Hunter, R., Overgaard, J. & Raleigh, J.A.: Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother. Oncol.  67: 35-44, 2003.

696.      Offersen, B.V., Borre, M. & Overgaard, J.: Quantification of angiogenesis as a prognostic marker in human carcinomas: A critical evaluation of histopathological methods for estimation of vascular density. Eur. J. Cancer 39: 881-890, 2003.

697.      Offersen, B.V., Nielsen, B.S., Høyer-Hansen, G., Rank, F., Hamilton-Dutoit, S., Overgaard, J. & Andreasen, P.A.: The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am. J. Pathol. 163: 1887-99, 2003.

698.      Offersen, B.V., Sørensen, F.B., Knoop, A. & Overgaard, J.: The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 43: 573-582, 2003.

699.      Overgaard, J.: Clinical trials are key to progress. Eur. J. Cancer. 39:133, 2003.

700.      Overgaard, J. & Brizel, D.M.: Does amifostine have a role during chemoradiation? Lancet Oncology 4: 378-381, 2003.

701.      Overgaard, J., Sand Hansen, H., Specht, L., Overgaard, M., Grau, C., Andersen, E., Bentzen, J., Bastholt, L., Hansen, O., Johansen, J., Andersen, L. & Evensen, J.F.: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 362: 933-940, 2003.

702.      Safwat, A., Aggerholm, N., Roitt, I., Overgaard, J. & Hokland, M.: Low-dose total body irradiation augments the therapeutic effect of Interleukin-2 in a mouse model for metastatic malignant melanoma. J. Exp. Ther. Oncol. 3: 161-68, 2003.

703.      Safwat, A., Bayoumy, Y., El-Sharkawy, N., Shaaban, K., Mansour, O. & Kamel, A.: The potential palliative role and possible immune modulatory effects of low-dose total body irradiation in relapsed or chemo-resistant non-Hodgkin's lymphoma. Radiother. Oncol. 69: 33-36, 2003.

704.      Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol. 123:433-9, 2003.

705.      Aaboe, M., Offersen, B.V., Christensen, A. & Andreasen, P.A.: Vitronectin in human breast carcinomas. Biochim. Biophys. Acta 1638: 72-82, 2003.